Use this URL to cite or link to this record in EThOS: https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.747385
Title: Effectiveness of sitagliptin vs sulphonylureas for managing type 2 diabetes mellitus in clinical practice
Author: Sharma, Manuj
ISNI:       0000 0004 7230 3019
Awarding Body: UCL (University College London)
Current Institution: University College London (University of London)
Date of Award: 2018
Availability of Full Text:
Access from EThOS:
Full text unavailable from EThOS. Please try the link below.
Access from Institution:
Abstract:
One challenging prescribing decision in type 2 diabetes mellitus (T2DM) is when clinicians must choose between sitagliptin and sulphonylureas as add-on to metformin based on effectiveness. Evidence on effectiveness of sitagliptin versus sulphonylureas as add-on to metformin was therefore systematically searched and revealed no study evaluating “real-world” comparative effectiveness of these treatments, particularly in older, more comorbid individuals. To address this gap, The Health Improvement Network, UK primary care database was used to extract a cohort of 26,844 individuals with T2DM prescribed these treatments and four cohort studies were undertaken to evaluate their comparative effectiveness. The first two studies demonstrated no difference in HbA1c reduction, approximately 12 months after initiating either treatment as add-on to metformin, however a significant comparative weight reduction with sitagliptin in those aged 18-75 (-2.26kg 95%CI -2.48 to -2.04) and ≥75 (-1.31kg 95%CI -1.96 to -0.66) was found. Two further studies revealed individuals prescribed sitagliptin were 11% more likely to record an undesirable HbA1c >58mmol/mol (Hazard Ratio 1.11 95%CI 1.06-1.16), however nearly twice as likely to record an anti-diabetic treatment change (HR 1.98 95%CI 1.86-2.10) compared to sulphonylurea initiators. This analysis on treatment change also highlighted an underlying inertia in both groups, as 66.4% of those prescribed sitagliptin and 83.7% prescribed sulphonylureas had no treatment change introduced despite recording a HbA1c >58 mmol/mol. This thesis provides “real-world” evidence that both sitagliptin and sulphonylureas are equally effective in lowering HbA1c and achieving glycaemic targets in a population that includes individuals aged ≥75 and with significant comorbidity. Sitagliptin is preferable for weight reduction. There is however, a substantial inertia in changing treatment when targets are not met, which is greater among sulphonylurea initiators. There remains a need to eliminate barriers preventing clinicians changing treatment when these two add-on medications prove inadequate, and further evaluate their longer-term comparative effectiveness.
Supervisor: Not available Sponsor: Not available
Qualification Name: Thesis (Ph.D.) Qualification Level: Doctoral
EThOS ID: uk.bl.ethos.747385  DOI: Not available
Share: